Evaluating genetic screening/counseling for patients diagnosed with prostate cancer who meet hereditary risk assessment based on NCCN Guidelines.
Ruben Ruiz Vega(Northeast Georgia Medical Center), Andrew Thomas Johnson(University of Colorado Denver), Aditya Ghosh(Northeast Georgia Medical Center), Oluseyi Abidoye(Mayo Clinic), Comfort Adewunmi(Piedmont Cancer Institute), Andria P. Caton(Northeast Georgia Medical Center)
Cited by 0
Related Papers
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population
|European Journal of Cancer|2024|47
Circulating Tumor DNA Testing for Minimal Residual Disease and Its Application in Colorectal Cancer
|Cells|2025|19
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population
|The Oncologist|2024|10